To date, most clinical trials in CRC have been conducted in patients with MSI-H mCRC and mainly targeted the PD-1/PD-L1 axis, demonstrating the efficacy of pembrolizumab [10] and nivolumab plus low-dose ipilimumab [11]. Here, CD274 is linked to colorectal carcinoma.